Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × lorukafusp alfa × Clear all
NCT00590824 2019-11-21

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

University of Wisconsin, Madison

Phase 2 Completed
23 enrolled 22 charts
Dermatologic

Melanoma

NCT00109863 2019-11-19

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

University of Wisconsin, Madison

Phase 2 Completed
14 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡